Please login to the form below

brodalumab

This page shows the latest brodalumab news and features for those working in and with pharma, biotech and healthcare.

Sun Pharma passes milestone with novel psoriasis drug approval

IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).

Latest news

AbbVie reports more solid data for would-be psoriasis blockbuster

ixekizumab) and Valeant’s Siliq (brodalumab).
Lilly claims another EU okay for Taltz

leader. A third IL-17 drug - Valeant’s Siliq (brodalumab) - was launched in the third quarter in the US at a discount to Cosentyx and Taltz but the company has yet
European Commission backs LEO Pharma’s Kyntheum

Novel biologic therapies such as brodalumab mean that achieving completely clear skin can now be a reality for people with moderate-to-severe psoriasis.”. ... Additionally, across all three trials, 56-61% of patients reported the skin condition no
Biosimilars eat into J&J's Remicade sales

brodalumab) - which claimed an earlier-than-expected FDA approval for psoriasis last week.
Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Meanwhile among other positive opinions granted by the CHMP was one for Leo Pharma's interleukin-17 inhibitor Kyntheum (brodalumab) - acquired from AstraZeneca - for plaque psoriasis.

More from news
Approximately 9 fully matching, plus 34 partially matching documents found.

Latest Intelligence

Pharma deals in September 2015

Brodalumab is phase III complete, but is thought to have been cast off due to concerns raised over links to the drug and suicidal thoughts. ... Collaboration - discovery. 500. AstraZeneca. Valeant Pharmaceuticals. Brodalumab for psoriasis, ready for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Client Services Director – Healthcare Advertising - London: Neg

Healthcare PR Director: £100, 000 – £120, 000 benefits

Client Services Director - Med Comms: Great salary and bebefits

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Editorial Team Leader, Medical Communications: Excellent package

Home based, Principal Medical Writer, Medical Communications: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Home based, Senior Medical Writer, Medical Communications: Excellent package

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Home based, Chief Medical Writer, Medical Communications: Excellent package

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Business Unit Head, Medical Communications, London: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Account Manager: £40, 000 - £45, 000 benefits

Editorial Director – Medical Education (MedComms): Neg

Subscribe to our email news alerts

PMHub

Add my company

Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....